152 related articles for article (PubMed ID: 37725377)
41. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
42. Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists and Risk of Pneumonia in Patients with Acute Stroke.
Momosaki R; Yasunaga H; Matsui H; Fushimi K; Abo M
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1035-1040. PubMed ID: 26853142
[TBL] [Abstract][Full Text] [Related]
43. No Increase in Risk of Acute Myocardial Infarction in Privately Insured Adults Prescribed Proton Pump Inhibitors vs Histamine-2 Receptor Antagonists (2002-2014).
Landi SN; Sandler RS; Pate V; Lund JL
Gastroenterology; 2018 Mar; 154(4):861-873.e6. PubMed ID: 29122546
[TBL] [Abstract][Full Text] [Related]
44. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.
Li X; Ostropolets A; Makadia R; Shoaibi A; Rao G; Sena AG; Martinez-Hernandez E; Delmestri A; Verhamme K; Rijnbeek PR; Duarte-Salles T; Suchard MA; Ryan PB; Hripcsak G; Prieto-Alhambra D
BMJ; 2021 Jun; 373():n1435. PubMed ID: 35727911
[TBL] [Abstract][Full Text] [Related]
45. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients.
O'Keefe GE; Gentilello LM; Maier RV
Ann Surg; 1998 Jan; 227(1):120-5. PubMed ID: 9445119
[TBL] [Abstract][Full Text] [Related]
46. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
47. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Lazarus B; Chen Y; Wilson FP; Sang Y; Chang AR; Coresh J; Grams ME
JAMA Intern Med; 2016 Feb; 176(2):238-46. PubMed ID: 26752337
[TBL] [Abstract][Full Text] [Related]
48. Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer.
Bianchi Porro G; Dicenta C; Cook T; Humphries TJ
J Clin Gastroenterol; 1987; 9 Suppl 2():14-8. PubMed ID: 2887613
[TBL] [Abstract][Full Text] [Related]
49. Comparison of roxatidine acetate and ranitidine in the treatment of reflux esophagitis. The Roxatidine Esophagitis Study Group.
Clin Ther; 1993; 15(2):283-93. PubMed ID: 8100189
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
[TBL] [Abstract][Full Text] [Related]
51. Effect of Ranitidine Intake on the Risk of Gastric Cancer Development.
Kim S; Lee S; Hong J; Ko I; Kim JY; Kim DK
Healthcare (Basel); 2021 Aug; 9(8):. PubMed ID: 34442208
[TBL] [Abstract][Full Text] [Related]
52. Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man.
Kawai K
Gastroenterol Jpn; 1992 Jun; 27(3):418-23. PubMed ID: 1624085
[TBL] [Abstract][Full Text] [Related]
53. Risks of long-term use of proton pump inhibitor on ischemic vascular events: A distributed network analysis of 5 real-world observational Korean databases using a common data model.
Kim Y; Seo SI; Lee KJ; Kim J; Yoo JJ; Seo WW; Shin WG
Int J Stroke; 2023 Jun; 18(5):590-598. PubMed ID: 36190338
[TBL] [Abstract][Full Text] [Related]
54. Ranitidine and nizatidine stimulate antral smooth muscle contractility via excitatory cholinergic mechanisms.
Parkman HP; Pagano AP; Ryan JP
Dig Dis Sci; 1998 Mar; 43(3):497-505. PubMed ID: 9539643
[TBL] [Abstract][Full Text] [Related]
55. A comparison of roxatidine acetate and ranitidine in duodenal ulcer healing.
Hüttemann W
Drugs; 1988; 35 Suppl 3():90-5. PubMed ID: 2905255
[TBL] [Abstract][Full Text] [Related]
56. Ranitidine Use and Gastric Cancer Among Persons with Helicobacter pylori.
Kumar S; Goldberg DS; Kaplan DE
Dig Dis Sci; 2022 May; 67(5):1822-1830. PubMed ID: 33856609
[TBL] [Abstract][Full Text] [Related]
57. Use of histamine H
Adelborg K; Sundbøll J; Schmidt M; Bøtker HE; Weiss NS; Pedersen L; Sørensen HT
Clin Epidemiol; 2018; 10():521-530. PubMed ID: 29765253
[TBL] [Abstract][Full Text] [Related]
58. Famotidine versus ranitidine for the short-term treatment of duodenal ulcer.
Simon B; Dammann HG; Jakob G; Miederer SE; Müller P; Ottenjann R; Paul F; Scholten T; Schütz E; Seifert E
Digestion; 1985; 32 Suppl 1():32-7. PubMed ID: 2866134
[TBL] [Abstract][Full Text] [Related]
59. Utilization and safety of proton-pump inhibitors and histamine-2 receptor antagonists in children and adolescents: an observational cohort study.
Ruigómez A; Johansson S; Nagy P; García Rodríguez LA
Curr Med Res Opin; 2017 Dec; 33(12):2201-2209. PubMed ID: 28699796
[TBL] [Abstract][Full Text] [Related]
60. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
Komazawa Y; Adachi K; Mihara T; Ono M; Kawamura A; Fujishiro H; Kinoshita Y
J Gastroenterol Hepatol; 2003 Jun; 18(6):678-82. PubMed ID: 12753150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
